< The 2014 All-America Research TeamRicky GoldwasserMorgan StanleyFirst-place appearances: 0

Total appearances: 7

Team debut: 2006Morgan Stanley’s Ricky Goldwasser holds on to the No. 2 position she first claimed in 2012. Clients appreciate the broad scope of her service: “In addition to basic coverage of companies,” says one fund manager, “Ricky is also very active in engaging consultants in the pharmaceuticals chain that provide valuable perspective on issues facing the sector.” Another supporter credits the analyst’s “deep institutional knowledge,” which enables her to “make adjustments to ‘adjusted [earnings per share]’ as reported by companies — to back out some of the fluff.” Goldwasser has been pounding the table about San Francisco–based McKesson Corp., a wholesale distributor of pharmaceuticals that supplies such retailers as Wal-Mart Stores and Target Corp. “In our view, McKesson is well positioned to gain additional generic wallet share in the core U.S. market, where Wal-Mart and Target provide key opportunities and catalysts,” she explains, “in addition to newly entered international markets.” Further, notes the analyst, “the sustained inflationary environment for generics provides McKesson with ongoing opportunities to expand margins and continue to generate free cash flow to support a well-balanced capital-deployment strategy.” In the small-cap space her top pick is chemistry outsourcer Albany Molecular Research in New York. The company’s new management team is providing “a clear path to growth through a combination of organic margin expansion opportunities augmented by strategic M&A,” she advises.